Rucaparib camsylate

{
  "id": "MLC-T-ONC-007519",
  "term": "Rucaparib camsylate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with certain types of prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. Rucaparib camsylate blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Rucaparib camsylate is a type of PARP inhibitor. Also called AG014699, PARP-1 inhibitor AG014699, and Rubraca.",
    "The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types."
  ],
  "synonyms": [
    "AG014699",
    "PARP-1 inhibitor AG014699",
    "Rubraca"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/rucaparib-camsylate/"
}